Predict your next investment

Cambridge Innovation Center company logo
Incubator/Accelerator
BUSINESS PRODUCTS & SERVICES | Facilities
cic.com

See what CB Insights has to offer

Founded Year

1999

Stage

Corporate Minority - II | Alive

Total Raised

$82.24M

Last Raised

$7.24M | 3 yrs ago

About Cambridge Innovation Center

Cambridge Innovation Center (CIC) is a office facility for growing technology and life sciences companies in the Greater Boston area. The Cambridge Innovation Center offers start-up and emerging companies facilities and business and technical services in a package which is designed to meet the needs of small and growing businesses.

Cambridge Innovation Center Headquarter Location

One Broadway 14th Floor, Kendall Square

Cambridge, Massachusetts, 02142,

United States

617-758-4100

Latest Cambridge Innovation Center News

Apollo Therapeutics Appoints Dr. Sanjay Aggarwal as Chief Medical Officer, Opens U.S. Facility

Nov 18, 2021

& CAMBRIDGE, England--( BUSINESS WIRE )--Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing transformative treatments based on breakthrough discoveries, today announced the appointment of Dr. Sanjay Aggarwal as the company’s chief medical officer. Dr. Aggarwal will be based in the company’s U.S. facility located at the Cambridge Innovation Center in Cambridge, Mass. “Sanjay is a highly accomplished clinical leader whose experience developing promising therapeutics through to regulatory approval will be incredibly valuable to Apollo as we move our lead programs forward,” said Dr. Richard Mason, CEO of Apollo. “We are proud to have him as a leader of our newly opened Boston facility where we look forward to growing our presence in the United States.” Dr. Aggarwal joins Apollo with more than 20 years in the biopharmaceutical industry, including extensive experience in building and leading clinical development teams, as well as a track record of taking drugs through development to successful regulatory approvals. Dr. Aggarwal was most recently chief medical officer at Angiocrine Bioscience, a clinical-stage cell and gene therapy company. Before this, he was the architect of the Rezurock™ (belumosudil) Phase 2 and 3 development programs at Kadmon, leading to its FDA approval for chronic graft versus host disease. Prior to joining Kadmon, Dr. Aggarwal was the global development lead for Kyprolis® (carfilzomib) at Amgen, leading to its approval in multiple myeloma in the U.S., E.U. and numerous additional countries. Earlier in his career, Dr. Aggarwal held positions of increasing responsibility in both biotech (Exelixis, Onyx Pharmaceuticals) and pharma (GSK, Novartis and Sanofi), overseeing development of early- and late-stage assets across several therapeutic areas with roles in the U.S., Europe and Asia-Pacific. He studied mathematics and medicine to earn his medical degree from The University of Cambridge. He has an MBA from The University of Chicago Booth School of Business. Clinically, he trained in internal medicine and public health and is a member of the Royal College of Physicians. “Apollo has built an impressive pipeline of therapeutic programs based on breakthrough discoveries that hold tremendous promise across multiple disease areas,” said Dr. Aggarwal. “I look forward to advancing the lead programs into clinical investigation and working with the team to further build the company by acquiring clinical-stage assets.” About Apollo Therapeutics Apollo Therapeutics is a portfolio-based biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading scientists and inventors, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo's model combines drug development 'architects' and deep subject matter experts to build an expansive and de-risked pipeline in oncology, major inflammatory disorders and rare disease. For more information, visit www.apollotherapeutics.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cambridge Innovation Center Patents

Cambridge Innovation Center has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/27/2005

6/19/2012

Aluminium compounds, Semiconductor device fabrication, Thin film deposition, Nanotechnology, Chemical processes

Grant

Application Date

6/27/2005

Grant Date

6/19/2012

Title

Related Topics

Aluminium compounds, Semiconductor device fabrication, Thin film deposition, Nanotechnology, Chemical processes

Status

Grant

Cambridge Innovation Center Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cambridge Innovation Center Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.